⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28098101 | 0.74 | TSHR (0.38) | — | |
| SCHEMBL28098099 | 0.74 | TSHR (0.38) | — | |
| SCHEMBL2235123 | 0.72 | ALDH1A1 (0.36) | — | |
| SCHEMBL28640063 | 0.71 | — | — | |
| SCHEMBL27546706 | 0.70 | — | — | |
| SCHEMBL2495478 | 0.70 | — | — | |
| SCHEMBL29956233 | 0.70 | — | — | |
| SCHEMBL23312 | 0.70 | — | — | |
| SCHEMBL31421734 | 0.70 | — | — | |
| SCHEMBL11256487 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024083220-A1 | LIGAND-OLIGONUCLEOTIDE CONJUGATE AND LINKER FOR CONJUGATE | 上海京新生物医药有限公司 | 2024-04-25 | — | — | WO | disclosed |
| US-20240131032-A1 | AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-25 | — | — | US | disclosed |
| EP-4355755-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20240123078-A1 | COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS | VIVIDION THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11957787-B2 | Wnt compositions and methods for purification | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240117363-A1 | PRODUCTION OF UNNATURAL NUCLEOTIDES USING A CRISPR/CAS9 SYSTEM | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-11 | — | — | US | disclosed |
| WO-2024043249-A1 | CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR | 富士フイルム株式会社 | 2024-02-29 | — | — | WO | disclosed |
| WO-2024043250-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | 富士フイルム株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-11879145-B2 | Reagents and methods for replication, transcription, and translation in semi-synthetic organisms | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230372536-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2023-11-23 | — | — | US | disclosed |
| US-8987414-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150051155-A1 | PEPTIDOMIMETIC MACROCYCLES | HOFFMANN-LA ROCHE, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8927500-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| EP-2061886-B1 | Small cationic immunomodulatory peptides | UNIV BRITISH COLUMBIA (CA) | 2014-05-07 | — | — | EP | disclosed |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| EP-2061886-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | The University of British Columbia (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008151434-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008022444-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-02-28 | — | — | WO | disclosed |